CN1316245A - Application of tea polyphenol and its oxide in treating muscular disease - Google Patents
Application of tea polyphenol and its oxide in treating muscular disease Download PDFInfo
- Publication number
- CN1316245A CN1316245A CN 00112820 CN00112820A CN1316245A CN 1316245 A CN1316245 A CN 1316245A CN 00112820 CN00112820 CN 00112820 CN 00112820 A CN00112820 A CN 00112820A CN 1316245 A CN1316245 A CN 1316245A
- Authority
- CN
- China
- Prior art keywords
- treatment
- purposes
- tea
- muscle
- tea polyphenols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001122767 Theaceae Species 0.000 title claims abstract description 73
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 50
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 50
- 208000021642 Muscular disease Diseases 0.000 title claims description 4
- 239000000049 pigment Substances 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 21
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract description 20
- 208000029578 Muscle disease Diseases 0.000 claims description 19
- 208000028872 Progressive muscular dystrophy Diseases 0.000 claims description 17
- 210000003205 muscle Anatomy 0.000 claims description 12
- 230000036541 health Effects 0.000 claims description 8
- 206010002027 Amyotrophy Diseases 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 208000025978 Athletic injury Diseases 0.000 claims description 3
- 208000034656 Contusions Diseases 0.000 claims description 3
- 206010061223 Ligament injury Diseases 0.000 claims description 3
- 206010050031 Muscle strain Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 201000009623 Myopathy Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 208000021945 Tendon injury Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 230000009519 contusion Effects 0.000 claims description 3
- 210000003041 ligament Anatomy 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 208000029308 periodic paralysis Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 238000005728 strengthening Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 208000004130 Blepharoptosis Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- -1 cyanine glycoside Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010039198 Risus sardonicus Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
An application of tea polyphenol and its oxide (tea pigment) in preparing medicine or health-care product to treat prograssive muscular dystrophy and myasthenia gravis with high curative effect is disclosed.
Description
The present invention relates to the new medicine use of tea polyphenols and oxide thereof (tea pigment), be specifically related to the application that tea polyphenols and oxide thereof (tea pigment) are used to prepare medicine or health product for treating muscle disease, belong to the field of Chinese medicines.
Tea polyphenols is the polyphenols that extracts from Folium Camelliae sinensis, comprises more than 30 kind of polyphenol components such as catechin, flavonoid glycosides, cyanine glycoside, phenolic acids, has stronger antioxygenic property.For the existing bibliographical information of the research of tea polyphenols.Multiple patent applications such as CN1142481A, CN1194966A, CN1186717A, CN1060488A, CN1071660A, CN1071844A, CN1056679A disclose the extracting method of tea polyphenols.The main body of tea polyphenols is a catechin, accounts for 70% to 80% of tea polyphenols substantially, and its oxidation product promptly is a tea pigment, comprises theaflavin, thearubigins and abrownin.The preparation method of tea pigment is tea polyphenols can be placed the air certain hour, autoxidation generation tea pigment; Also tea polyphenols heated oxide soluble in water can be generated tea pigment; Also can from Folium Camelliae sinensis, extract with patent application disclosed methods such as CN1081575A, CN1074459A, CN1074618A.The tea polyphenols and the oxide (tea pigment) thereof that obtain with these methods can be used as medicinal.Medical value report for tea polyphenols and oxide (tea pigment) thereof may be summarized to be antitumor, blood fat reducing, blood sugar lowering, blood pressure lowering, cholesterol reducing, atherosclerosis, prevention and treatment cardiovascular disease.But up to the present, relevant tea polyphenols of Shang Weijian and oxide (tea pigment) thereof are used for the treatment of muscle disease, especially for the report of treatment progressive muscular dystrophy and myasthenia gravis.
The present inventor is used for the treatment of muscle disease with regard to tea polyphenols and oxide (tea pigment) thereof and has carried out long term studies, thereby finished the present invention.
A kind of new medicinal usage that the purpose of this invention is to provide tea polyphenols and oxide thereof (tea pigment), be that tea polyphenols and oxide thereof (tea pigment) are used to prepare medicine or health product for treating muscle disease, particularly treat the new purposes of progressive muscular dystrophy and myasthenia gravis.
Muscle disease is the obstacle owing to the muscle different parts, as the neural muscle disease that causes with neuromuscular junction place obstacle, sarolemma dysfunction, muscle fiber obstacle etc.Comprising progressive muscular dystrophy, myasthenia gravis, periodic paralysis, tetanic property myopathy, polymyositis, amyotrophy, class myasthenia gravis etc., is typical case and refractory with progressive muscular dystrophy and myasthenia gravis.The cardinal symptom of muscle disease is that muscle is very easily tired, muscle tone is too high or too low, amyotrophy and becoming thin.In addition, Progressive Muscular Dystrophy Patients is also walked slowly, is easily stumbled, walking swings up and down; The myasthenia gravis patient then blepharoptosis, diplopia, witless expression, risus sardonicus, shut up that order is tight, dysphagia; Periodic paralysis patient then muscle is periodically loose collapsing from physical exhaustion; Tetanic property myopathy patient muscle rigidity, loose difficulty; Polymyositis is then involved acra, neck, pharyngeal and whole-body muscle; Amyotrophy patient skeletal muscle volume reduces, muscle fiber reduces or attenuate, even disappears.This class disease, especially progressive muscular dystrophy and myasthenia gravis do not have specific medicine and method at present.Western medical treatment, anticholinergic medicine commonly used, prednisone, cyclophosphamide etc.Chinese traditional treatment, many invigorating the spleen and replenishing QI, the whole body conditioning, but adaptive surface is too wide, at not obvious.To progressive muscular dystrophy and myasthenia gravis, still lack effective radical cure medicine.Therefore, seek a kind ofly to muscle disease, particularly the natural drug that progressive muscular dystrophy and myasthenia gravis are had a remarkable therapeutic effect is very important, and tea polyphenols and oxide thereof (tea pigment) have been obtained excellent curative in this respect.
Tea polyphenols of the present invention and oxide thereof (tea pigment) have multiple preparation method, belong to already known processes and mature technology, and existing commodity selling.
Tea polyphenols of the present invention and oxide thereof (tea pigment) are a kind of active constituents of medicine, preparation process according to routine, can be main active constituent with tea polyphenols and/or Tea pigment (tea pigment), add excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
Because the present invention discloses tea polyphenols and oxide (tea pigment) treatment muscle disease thereof first; particularly treat the pharmacologic action of progressive muscular dystrophy and myasthenia gravis; therefore; tea polyphenols and/or Tea pigment (tea pigment) are cooperated the making medicament separately or with other active constituent or adjuvant; as long as this medicament is used for the treatment of muscle disease; especially for treatment progressive muscular dystrophy and myasthenia gravis, all belong to protection scope of the present invention.
Tea polyphenols of the present invention and oxide thereof (tea pigment) all have the effect of treatment muscle disease when making any dosage form.Any medicament; if contain tea polyphenols and/or tea pigment in its component or only prepare patent medicine with tea polyphenols and/or tea pigment; on signs such as its packing or description; and on other any propaganda materials; as long as indicate or point out and have the treatment muscle disease; the effect of treatment progressive muscular dystrophy and myasthenia gravis is particularly arranged, then fall within protection scope of the present invention.
Tea polyphenols of the present invention and oxide thereof (tea pigment) derive from the natural plants Folium Camelliae sinensis of medicine-food two-purpose, therefore, tea polyphenols and/or tea pigment can be made health food or health care medicine.Health food or the health care medicine made with tea polyphenols and/or tea pigment; if on signs such as its packing or description, indicate or point out and have the treatment muscle disease; the effect of treatment progressive muscular dystrophy and myasthenia gravis is particularly arranged, also fall within protection scope of the present invention.
Tea polyphenols of the present invention and oxide thereof (tea pigment) also can strengthen and improve muscle blood and nutrition supply, eliminate muscle fatigue, recover and the increase muscle strength.Especially for ligament and tendon injury, muscle sprain and soft tissue contusion and tendinitis can fast and effeciently treat and recover for athletic injury.Therefore, also can be used as athlete and motion back elimination myalgia and fatigue, recover the medicine or the health product of muscular strength and muscle power.Any medicine or health product; if contain tea polyphenols and/or tea pigment in its component or only be prepared from tea polyphenols and/or tea pigment; on signs such as its packing or description; and on any other propaganda material; as long as indicate or point out to have and eliminate myalgia and fatigue as athlete or motion back; strengthen or improve muscle blood and nutrition supply; recover and increase the effect of muscle strength or muscle power; and to athletic injury; especially ligament and tendon injury; muscle sprain; soft tissue contusion and tendinitis have treatment and restitution, also fall within protection scope of the present invention.
Embodiment 1
Prescription
Tea polyphenols 800 grams
Medical starch 200 grams
Above-mentioned component is stirred, encapsulated, every filling 0.5 gram.Make 2000 of tea polyphenols capsules, every capsules contains 400 milligrams of tea polyphenols.
Embodiment 2
Tea polyphenols 250 grams
2000 milliliters of distilled water
Stevioside 1 gram
Tea polyphenols is dissolved in stirring and evenly mixing in the distilled water, adds stevioside, stirring and evenly mixing is bottled once more, and every bottled 10 milligrams, sterilization makes the tea polyphenols oral liquid.
Embodiment 3
Prescription
Tea polyphenols 15 grams
White sugar 50 grams
Citric acid 5 grams
Carbonated water 930 grams
A small amount of Herba Menthae, vanilla
Various raw materials are mixed, stir, bottle, make the tea polyphenols beverage.
The medicine of tea polyphenols of the present invention and oxide thereof (tea pigment) preparation is taken checking through 63 routine patients, and to muscle disease, particularly progressive muscular dystrophy and myasthenia gravis all have good curative effect.According to age, body weight, condition of illness, patient takes 0.5-1.2 gram tea polyphenols and/or tea pigment at every turn, every day three times, after meal or take one and a half hours ante cibum, positive effect is promptly arranged behind the first quarter moon, muscle disease patient's muscle fatigue, muscle weakness, amyotrophy and the symptom of becoming thin obviously alleviate, and Progressive Muscular Dystrophy Patients walking flexibility ratio increases, and paces are steady; Symptoms such as myasthenia gravis patient's blepharoptosis, diplopia, witless expression are obviously improved.After half a year, the patient with slight symptoms can fully recover, and the patient with severe symptoms significantly takes a turn for the better.Take tea polyphenols of the present invention and oxide thereof (tea pigment) treatment muscle disease, particularly treat progressive muscular dystrophy and myasthenia gravis, total effective rate 98%, obvious effective rate is more than 94%.
The present invention has enlarged the range of application of tea polyphenols and oxide (tea pigment) thereof, has improved its exploitation and has been worth.With tea polyphenols of the present invention and oxide (tea pigment) treatment muscle disease thereof, particularly treat progressive muscular dystrophy and myasthenia gravis, special effect, remarkable, compound method is simple, raw material is easy to get, and does not see toxic and side effects after taking.
Claims (10)
1, a kind of new purposes of making the medicine or the health product of raw material with tea polyphenols and/or Tea pigment (tea pigment), it is characterized in that tea polyphenols and/or Tea pigment (tea pigment) are cooperated making medicine or health product separately or with other drug active constituent or adjuvant, be used for the treatment of the new purposes of muscle disease.
2,, it is characterized in that being used for the treatment of progressive muscular dystrophy according to the purposes of claim 1.
3,, it is characterized in that being used for the treatment of myasthenia gravis according to the purposes of claim 1.
4,, it is characterized in that being used for the treatment of periodic paralysis according to the purposes of claim 1.
5,, it is characterized in that being used for the treatment of tetanic property myopathy according to the purposes of claim 1.
6,, it is characterized in that being used for the treatment of polymyositis according to the purposes of claim 1.
7,, it is characterized in that being used for the treatment of amyotrophy according to the purposes of claim 1.
8,, it is characterized in that being used for the treatment of the class myasthenia gravis according to the purposes of claim 1.
9,, it is characterized in that being used for strengthening or improve muscle blood and nutrition supply, elimination myalgia and fatigue, promotion muscular strength and antisecosis after athlete and the motion according to the purposes of claim 1.
10,, it is characterized in that being used for the treatment of athletic injury, especially ligament and tendon injury, muscle sprain, soft tissue contusion and tendinitis according to the purposes of claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001128205A CN1163228C (en) | 2000-04-03 | 2000-04-03 | Application of tea polyphenol and its oxide in treating muscular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001128205A CN1163228C (en) | 2000-04-03 | 2000-04-03 | Application of tea polyphenol and its oxide in treating muscular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1316245A true CN1316245A (en) | 2001-10-10 |
| CN1163228C CN1163228C (en) | 2004-08-25 |
Family
ID=4582654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001128205A Expired - Fee Related CN1163228C (en) | 2000-04-03 | 2000-04-03 | Application of tea polyphenol and its oxide in treating muscular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1163228C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007020917A1 (en) * | 2005-08-18 | 2007-02-22 | The University Of Tokushima | Agent for enhancing and prolonging utrophin production and processed food comprising the same |
| CN1332667C (en) * | 2004-05-26 | 2007-08-22 | 中国科学院生物物理研究所 | Compound preparation for resisting Parkinson's disease |
| JP2010111608A (en) * | 2008-11-05 | 2010-05-20 | Kao Corp | Muscle damage inhibitor |
| CN109073636A (en) * | 2016-04-27 | 2018-12-21 | 化工产品开发公司Seppic | Method for assessing the ability of composition prevention muscle damage and fatigue；Food supplement and drug |
-
2000
- 2000-04-03 CN CNB001128205A patent/CN1163228C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332667C (en) * | 2004-05-26 | 2007-08-22 | 中国科学院生物物理研究所 | Compound preparation for resisting Parkinson's disease |
| WO2007020917A1 (en) * | 2005-08-18 | 2007-02-22 | The University Of Tokushima | Agent for enhancing and prolonging utrophin production and processed food comprising the same |
| JP2010111608A (en) * | 2008-11-05 | 2010-05-20 | Kao Corp | Muscle damage inhibitor |
| CN109073636A (en) * | 2016-04-27 | 2018-12-21 | 化工产品开发公司Seppic | Method for assessing the ability of composition prevention muscle damage and fatigue；Food supplement and drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1163228C (en) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2891496B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING COMPLEX EXTRACT OF CRATAEGI FRUCTUS and CITRI PERICARPIUM AS AN ACTIVE INGREDIENT FOR TREATING OR PREVENTING OBESITY OR LIPID-RELATED METABOLIC DISEASES | |
| Saad et al. | Anti-obesity medicinal plants | |
| CN1163228C (en) | Application of tea polyphenol and its oxide in treating muscular disease | |
| RU2408383C1 (en) | Composition with antineoplastic and adaptogenic activity (versions) and based drug (versions) | |
| CN1192771C (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN1119114A (en) | Seabuckthorn fruit flavone oral liquid and preparing process thereof | |
| Chevallier | Herbal remedies | |
| CN1370528A (en) | Medicine for treating insomnia and mental disturbance | |
| CN106177634A (en) | A kind of weight-reducing compound preparation and preparation method thereof | |
| CN1172667C (en) | Application of tea polyphenol in treating thyroid disease | |
| CN1316244A (en) | Application of tea polyphenol in treating kidney disease | |
| CN1173699C (en) | Medicine for treating lupus erythematosus | |
| CN1335129A (en) | Gynopathy treating medicine | |
| CN1213743C (en) | New use of tea polyphenols for treating prostatosis | |
| CN1314149A (en) | New use of tea polyphenols and its oxide for treating hepatopathy | |
| CN1353988A (en) | Medicine for curing osteopathy | |
| CN1328821A (en) | Medicine for curing psoriasis | |
| CN1352942A (en) | Medicine for treating tuberculosis | |
| CN1316243A (en) | Application of tea polyphenol and its oxide in treating anemia | |
| CN1352943A (en) | Medicine for treating disease of motor neuron | |
| CN1328822A (en) | Medicine for curing Parkinson's disease | |
| CN101450072A (en) | Lily polysaccharide nutrient health-care oral liquid | |
| CN1370529A (en) | Medicine for treating spinal cord lesion | |
| CN1324617A (en) | Medicine for treating hyperosteogeny and protrusion of lumber intervertebral disc | |
| CN1065756C (en) | Application of theachrome in preparing medicine for prostatauxe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |